Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia

In X‐linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH](2)D) concentrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoping, Imel, Erik A., Ruppe, Mary D., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey, Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Carpenter, Thomas O., Peacock, Munro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042055/
https://www.ncbi.nlm.nih.gov/pubmed/26073451
http://dx.doi.org/10.1002/jcph.570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042055/
https://www.ncbi.nlm.nih.gov/pubmed/26073451
http://dx.doi.org/10.1002/jcph.570

Ejemplares similares